-
Where do male services fit in the picture when it comes to your facility? While most family planning centers report a percentage of male patients who receive sexually transmitted infection care (74%) and contraceptive care (68%), males make up only 5% nationally of their overall caseload.
-
More women are taking a second look at the intrauterine device (IUD) for contraception. IUD insertions went up 23% between January 2008 and January 2009, according to SDI Health, a health care analytics firm in Plymouth Meeting, PA.
-
FDA Advisory Committee recommends approval of dabigatran, safety of proton pump inhibitors, effectiveness of glucosamine and chondroitin, FDA Actions.
-
-
-
Ever since 1796, when Edward Jenner introduced the world's first vaccine against smallpox, the role of vaccination has arguably become one of the most important advances in medicine.
-
The incretin class of medications (exenatide, liraglutide, sitagliptin, saxagliptin) all share the favorable quality of not being associated with weight gain.
-
A recombinant, polyethylene glycol (PEG) mammalian urate oxidase (uricase) has been approved by the FDA for treatment of hyperuricemia. Uricase metabolizes urate to allantoin, a water-soluble metabolite, which is cleared renally. Pegliticase is marketed by Savient Pharmaceuticals as Krystexxa™.
-
A systematic review shows that the three classical symptoms of paroxysmal cough, post-tussive emesis, and inspiratory whoop are helpful for the diagnosis, but cannot be relied upon to rule in or rule out pertussis as the cause of a chronic cough.
-
Initiating treatment for hypercholesterolemia at age 30 years instead of age 60 years might very well prevent not just 30% of the CAD events as occurred in the 5-year statin trials, but perhaps as many as 60% of the CAD events lifetime.